FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2433997999> ?p ?o ?g. }

• W2433997999 endingPage "44595" @default.
• W2433997999 startingPage "44583" @default.
• W2433997999 abstract "// Bo Ai 1 , Huiquan Liu 2 , Yu Huang 2 , Ping Peng 2 1 Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan 430030, People’s Republic of China 2 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan 430030, People’s Republic of China Correspondence to: Ping Peng, email: pengpingtjh@163.com Keywords: circulating cell-free DNA, non-small cell lung cancer, prognosis, biomarker, meta-analysis Received: February 28, 2016      Accepted: May 29, 2016      Published: June 15, 2016 ABSTRACT Circulating cell-free DNA (cfDNA), which can be obtained from plasma or serum by non-invasive procedures, has showed great potential to predict treatment response and survival for cancer patients. Several studies have assessed the prognostic and predictive value of cfDNA in non-small cell lung cancer (NSCLC). However, these studies were often small and reported varying results. To address this issue, a meta-analysis was carried out. A total of 22 studies involving 2518 patients were subjected to the final analysis. Our results indicated that NSCLC patients with higher cfDNA concentration had shorter median progression-free survival (PFS) and overall survival (OS) time. In addition, high levels of cfDNA were significantly associated with poor PFS (hazard ratio or HR, 1.32; 95% CI, 1.02-1.71) and OS (HR, 1.64; 95% CI, 1.26-2.15). With respect to tumor specific mutations, we failed to reveal significant differences for PFS (HR, 1.30; 95% CI, 0.66-2.56) and OS (HR, 1.05; 95% CI, 0.49-2.25) when NSCLC patients were grouped according to KRAS genotype detected in cfDNA. However, NSCLC patients which harbored EGFR activating mutation in cfDNA had a greater chance of response to EGFR-TKIs (odds ratio or OR, 1.96; 95% CI, 1.59-2.42). No significant publication bias was detected in this study. In conclusion, cfDNA could act as a prognostic and predictive biomarker for patients with NSCLC." @default.
• W2433997999 created "2016-06-24" @default.
• W2433997999 creator A5059105795 @default.
• W2433997999 creator A5067658463 @default.
• W2433997999 creator A5080052541 @default.
• W2433997999 creator A5088082429 @default.
• W2433997999 date "2016-06-15" @default.
• W2433997999 modified "2023-10-14" @default.
• W2433997999 title "Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer" @default.
• W2433997999 cites W1480161907 @default.
• W2433997999 cites W1497100470 @default.
• W2433997999 cites W1690635788 @default.
• W2433997999 cites W1805253056 @default.
• W2433997999 cites W1940455451 @default.
• W2433997999 cites W1960894474 @default.
• W2433997999 cites W1969349257 @default.
• W2433997999 cites W1969965824 @default.
• W2433997999 cites W1973649349 @default.
• W2433997999 cites W1978285367 @default.
• W2433997999 cites W1978527867 @default.
• W2433997999 cites W1979671400 @default.
• W2433997999 cites W1982405354 @default.
• W2433997999 cites W1983466841 @default.
• W2433997999 cites W1991835829 @default.
• W2433997999 cites W1995321875 @default.
• W2433997999 cites W1998141448 @default.
• W2433997999 cites W1999263306 @default.
• W2433997999 cites W2000484387 @default.
• W2433997999 cites W2010367254 @default.
• W2433997999 cites W2013768132 @default.
• W2433997999 cites W2014810018 @default.
• W2433997999 cites W2015000811 @default.
• W2433997999 cites W2015117608 @default.
• W2433997999 cites W2015343563 @default.
• W2433997999 cites W2017059033 @default.
• W2433997999 cites W2032974400 @default.
• W2433997999 cites W2040604770 @default.
• W2433997999 cites W2042681889 @default.
• W2433997999 cites W2054133698 @default.
• W2433997999 cites W2064991155 @default.
• W2433997999 cites W2074791509 @default.
• W2433997999 cites W2075097436 @default.
• W2433997999 cites W2076466060 @default.
• W2433997999 cites W2084881004 @default.
• W2433997999 cites W2097560495 @default.
• W2433997999 cites W2100691227 @default.
• W2433997999 cites W2103077070 @default.
• W2433997999 cites W2111448780 @default.
• W2433997999 cites W2128165330 @default.
• W2433997999 cites W2131550900 @default.
• W2433997999 cites W2144214560 @default.
• W2433997999 cites W2145643405 @default.
• W2433997999 cites W2150361756 @default.
• W2433997999 cites W2166749501 @default.
• W2433997999 cites W2170568643 @default.
• W2433997999 cites W2173105601 @default.
• W2433997999 cites W2174055773 @default.
• W2433997999 cites W2176058427 @default.
• W2433997999 cites W2189406087 @default.
• W2433997999 cites W2206684187 @default.
• W2433997999 cites W2206697844 @default.
• W2433997999 cites W2276207172 @default.
• W2433997999 cites W2281580962 @default.
• W2433997999 cites W247981852 @default.
• W2433997999 cites W2917837889 @default.
• W2433997999 doi "https://doi.org/10.18632/oncotarget.10069" @default.
• W2433997999 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5190120" @default.
• W2433997999 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27323821" @default.
• W2433997999 hasPublicationYear "2016" @default.
• W2433997999 type Work @default.
• W2433997999 sameAs 2433997999 @default.
• W2433997999 citedByCount "69" @default.
• W2433997999 countsByYear W24339979992016 @default.
• W2433997999 countsByYear W24339979992017 @default.
• W2433997999 countsByYear W24339979992018 @default.
• W2433997999 countsByYear W24339979992019 @default.
• W2433997999 countsByYear W24339979992020 @default.
• W2433997999 countsByYear W24339979992021 @default.
• W2433997999 countsByYear W24339979992022 @default.
• W2433997999 countsByYear W24339979992023 @default.
• W2433997999 crossrefType "journal-article" @default.
• W2433997999 hasAuthorship W2433997999A5059105795 @default.
• W2433997999 hasAuthorship W2433997999A5067658463 @default.
• W2433997999 hasAuthorship W2433997999A5080052541 @default.
• W2433997999 hasAuthorship W2433997999A5088082429 @default.
• W2433997999 hasBestOaLocation W24339979991 @default.
• W2433997999 hasConcept C121608353 @default.
• W2433997999 hasConcept C126322002 @default.
• W2433997999 hasConcept C143998085 @default.
• W2433997999 hasConcept C207103383 @default.
• W2433997999 hasConcept C2776256026 @default.
• W2433997999 hasConcept C2781197716 @default.
• W2433997999 hasConcept C44249647 @default.
• W2433997999 hasConcept C55493867 @default.
• W2433997999 hasConcept C71924100 @default.
• W2433997999 hasConcept C86803240 @default.
• W2433997999 hasConceptScore W2433997999C121608353 @default.
• W2433997999 hasConceptScore W2433997999C126322002 @default.

• next